Pricing Log in Create free account
Sunday 11 October 2026 Export all ABBV data to Excel Powerpack

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

276.47 4.05 +1.49%
Market cap
$481.4B
P/E
78.1×
Fwd P/E
27.8×
Dividend yield
3.10%
F-score
8/9
Altman Z
2.31
Beneish M
−2.86
Dividend safety
44/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

AbbVie Inc. 10-K filed Feb 20, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 2:38 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1A, Risk Factors, against the 10-K filed Feb 14, 2025: 11 added · 22 modified; 14 with only figures updated

33 more changes in this Item, word by word, in Powerpack.

Powerpack